All In Biotech

Drug Trial Radar · NCT06699108

Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy

A Multi-Center, Randomized, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VGR-R01 in Subjects With Bietti Crystalline Dystrophy

Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Dec 13, 2024

Primary completion

Dec 1, 2026

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3 study to evaluate the efficacy and safety of VGR-R01 in subjects with Bietti Crystalline Dystrophy. This is a multicenter, randomized controlled study which will enroll 45 subjects.

Conditions

  • Bietti Crystalline Dystrophy
  • Inherited Retinal Diseases

Interventions

  • VGR-R01Drug

    Subretinal injection of VGR-R01 (0.1 mL)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with change in BCVA in the study eyes of BCD subjects as assessed by ETDRSTime frame: Baseline up to Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Vitalgen Biopharma Co.,Ltd.

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.